Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018

[1]  Tueng T. Shen,et al.  Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study , 2020, The Lancet. Global health.

[2]  M. Fornage,et al.  Twenty-seven-year time trends in dementia incidence in Europe and the United States , 2020, Neurology.

[3]  P. Bernillon,et al.  Is the type 2 diabetes epidemic plateauing in France? A nationwide population-based study. , 2020, Diabetes & metabolism.

[4]  Sonia M. Thomas,et al.  Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis , 2019, BMJ Open.

[5]  E. Oger,et al.  French administrative health care database (SNDS): The value of its enrichment. , 2019, Therapie.

[6]  J. Cunha-Vaz,et al.  Incidence of Age-Related Macular Degeneration in the Central Region of Portugal: The Coimbra Eye Study – Report 5 , 2019, Ophthalmic Research.

[7]  M. Goldberg,et al.  Identifying diabetes cases in health administrative databases: a validation study based on a large French cohort , 2018, International Journal of Public Health.

[8]  C. Creuzot-Garcher,et al.  Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti–Vascular Growth Factor Agents in a Nationwide Study in France , 2018, JAMA ophthalmology.

[9]  P. Mitchell,et al.  Age-related macular degeneration , 2018, The Lancet.

[10]  J. Dartigues,et al.  Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study , 2018, JAMA ophthalmology.

[11]  J. Coste,et al.  Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. , 2017, Revue d'epidemiologie et de sante publique.

[12]  Yara T. E. Lechanteur,et al.  Prevalence of Age-Related Macular Degeneration in Europe , 2017, Ophthalmology.

[13]  Nicholas Moore,et al.  The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology , 2017, Pharmacoepidemiology and drug safety.

[14]  R. Klein,et al.  Incidence of Age-Related Macular Degeneration in a Multi-Ethnic United States Population: The Multi-Ethnic Study of Atherosclerosis. , 2016, Ophthalmology.

[15]  H. Jacqmin-Gadda,et al.  Trends in dementia incidence: Evolution over a 10-year period in France , 2016, Alzheimer's & Dementia.

[16]  J. Cunha-Vaz,et al.  Age‐related macular degeneration in Portugal: prevalence and risk factors in a coastal and an inland town. The Coimbra Eye Study – Report 2 , 2016, Acta ophthalmologica.

[17]  P. Mitchell,et al.  The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study. , 2015, Ophthalmology.

[18]  C. Tzourio,et al.  The Montrachet Study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population , 2015, Acta ophthalmologica.

[19]  I. Carrière,et al.  Incidence and Characteristics of Cataract Surgery in France from 2009 to 2012: A National Population Study. , 2015, Ophthalmology.

[20]  T. Peto,et al.  Prevalence of age-related macular degeneration in the Republic of Ireland , 2015, British Journal of Ophthalmology.

[21]  R. Klein,et al.  Age-related macular degeneration and mortality in community-dwelling elders: the age, gene/environment susceptibility Reykjavik study. , 2015, Ophthalmology.

[22]  F. Gueyffier,et al.  Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. , 2014, JAMA ophthalmology.

[23]  F. Holz,et al.  Recent developments in the treatment of age-related macular degeneration. , 2014, The Journal of clinical investigation.

[24]  N. Pfeiffer,et al.  Prevalence of age-related macular degeneration in a large European cohort: Results from the population-based Gutenberg Health Study , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.

[25]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[26]  Tunde Peto,et al.  Prevalence of age-related macular degeneration in elderly Caucasians: the Tromsø Eye Study. , 2012, Ophthalmology.

[27]  M. Goldacre,et al.  Trends over time and geographical variation in rates of intravitreal injections in England , 2011, British Journal of Ophthalmology.

[28]  E. Stefánsson,et al.  Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load , 2011, British Journal of Ophthalmology.

[29]  B. Nan,et al.  Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. , 2011, American journal of ophthalmology.

[30]  R. Klein,et al.  Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study. , 2011, Ophthalmology.

[31]  K. Fushimi,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[32]  R. Klein,et al.  Prevalence of age-related macular degeneration in the US population. , 2011, Archives of ophthalmology.

[33]  P. España,et al.  Prevalence of age-related macular degeneration in Spain , 2011, British Journal of Ophthalmology.

[34]  P. Barberger‐Gateau,et al.  Nutrition and age-related eye diseases: The Alienor (Antioxydants, lipides essentiels, nutrition et maladies oculaires) study , 2010, The journal of nutrition, health & aging.

[35]  R. Klein,et al.  Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. , 2010, American journal of ophthalmology.

[36]  C. Delcourt,et al.  The three-year incidence of age-related macular degeneration: the "Pathologies Oculaires Liées à l'Age" (POLA) prospective study. , 2005, American journal of ophthalmology.

[37]  Mina Torres,et al.  Prevalence of lens opacities in Latinos: the Los Angeles Latino Eye Study. , 2004, Ophthalmology.

[38]  A. Bird,et al.  The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. , 2003, Acta ophthalmologica Scandinavica.

[39]  C. Delcourt,et al.  Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study , 2001, Ophthalmic epidemiology.

[40]  C. Delcourt,et al.  Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age. , 1998, Archives of ophthalmology.